GNRSW logo

Greenrose Acquisition Corp. (GNRSW) Hisse Analizi

Yalnızca bilgilendirme amaçlıdır. Finansal tavsiye değildir. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

GNRSW, $ (piyasa değeri 0) fiyatla Healthcare işi olan Greenrose Acquisition Corp.'i temsil ediyor. Büyüme potansiyeli, finansal sağlık ve momentum konusunda 43/100 (ihtiyatlı) olarak derecelendirilmiştir.

Son analiz: 18 Mar 2026
43/100 AI Puanı

Greenrose Acquisition Corp. (GNRSW) Sağlık ve Boru Hattı Genel Bakışı

CEONicole Conboy
Çalışanlar91
Halka Arz Yılı2020
SektörHealthcare

Greenrose Holding Company Inc. cultivates, processes, and packages medical cannabis and derivative products, positioning itself within the specialty and generic drug manufacturing segment of the healthcare sector. Founded in 2014, the company aims to serve the growing demand for medical cannabis products amidst evolving regulations and market dynamics.

Veri Kaynağı | Finansal Veriler Kantitatif Analiz NASDAQ Analiz: 18 Mar 2026

Yatırım Tezi

Greenrose Holding Company Inc. presents a speculative investment opportunity within the evolving cannabis industry. With a market capitalization of $0.00B and a high beta of 3309.14, the stock demonstrates significant volatility. The company's reported profit margin of 70.6% and gross margin of 59.1% suggest potential profitability, but these figures need to be validated with consistent performance over time. Growth catalysts include the expansion of legal cannabis markets and the development of new cannabis-based products. However, the company faces risks related to regulatory uncertainty, competition, and the challenges of operating in the OTC market. Investors should carefully assess the company's financial stability, operational efficiency, and ability to navigate the complex regulatory landscape before considering an investment. The lack of a dividend yield reflects a focus on reinvesting earnings for growth.

FMP finansallarına ve nicel analizine dayanmaktadır

Temel Önemli Noktalar

  • Profit Margin of 70.6% indicates strong potential profitability, though it needs to be sustained over time.
  • Gross Margin of 59.1% suggests efficient cost management in the production and sale of cannabis products.
  • Beta of 3309.14 indicates extremely high volatility compared to the broader market.
  • Market Cap of $0.00B reflects the company's small size and potential for growth or instability.
  • The company does not offer a dividend, suggesting a focus on reinvesting earnings for future expansion.

Rakipler & Benzerleri

Güçlü Yönler

  • Vertically integrated operations.
  • High profit margin (70.6%).
  • Established presence in specific markets.
  • Focus on medical cannabis.

Zayıflıklar

  • OTC listing indicates higher risk and lower liquidity.
  • High beta (3309.14) indicates extreme volatility.
  • Small market capitalization ($0.00B).
  • Limited financial information available.

Katalizörler

  • Upcoming: Potential changes in cannabis regulations at the state or federal level could create new market opportunities.
  • Ongoing: Expansion of the company's product line to include new cannabis-based therapies.
  • Ongoing: Strategic partnerships with other companies in the cannabis industry to expand market reach.
  • Upcoming: Positive results from clinical trials of the company's cannabis-based products.
  • Ongoing: Increasing acceptance and legalization of cannabis for medical purposes.

Riskler

  • Potential: Regulatory uncertainty and changes in cannabis laws could negatively impact the company's operations.
  • Ongoing: Intense competition from other cannabis producers could erode market share and profitability.
  • Potential: Price volatility in the cannabis market could impact the company's revenue and earnings.
  • Ongoing: Challenges of operating in the OTC market, including limited liquidity and disclosure requirements.
  • Potential: Negative publicity or reputational damage could harm the company's brand image.

Büyüme Fırsatları

  • Expansion into New Markets: As more states and countries legalize cannabis for medical or recreational use, Greenrose has the opportunity to expand its geographic reach. This includes establishing cultivation and distribution facilities in new markets, either organically or through acquisitions. The global legal cannabis market is projected to reach $42.7 billion by 2027, presenting a significant opportunity for Greenrose to increase its revenue and market share. Timeline: Ongoing, dependent on regulatory changes and market entry strategies.
  • Product Innovation and Development: Greenrose can invest in research and development to create new and innovative cannabis-based products, such as novel formulations, delivery methods, or therapeutic applications. This can help the company differentiate itself from competitors and capture a larger share of the market. The market for cannabis-infused products is growing rapidly, with consumers seeking new and convenient ways to consume cannabis. Timeline: Ongoing, with new products potentially launching within the next 1-3 years.
  • Strategic Partnerships and Acquisitions: Greenrose can pursue strategic partnerships or acquisitions to expand its capabilities, access new markets, or consolidate its position in existing markets. This could include partnering with other cannabis companies, pharmaceutical companies, or research institutions. The cannabis industry is undergoing consolidation, with larger companies acquiring smaller players to gain scale and market share. Timeline: Ongoing, with potential deals occurring within the next 1-2 years.
  • Development of Branded Products: Creating strong, recognizable brands can help Greenrose build customer loyalty and differentiate itself from competitors. This includes investing in marketing, advertising, and packaging to create a consistent brand image. The cannabis market is becoming increasingly brand-conscious, with consumers seeking out trusted and reputable brands. Timeline: Ongoing, with brand development efforts continuing over the next several years.
  • Focus on Medical Cannabis: Greenrose can focus on the medical cannabis market, which offers higher margins and greater regulatory certainty compared to the recreational market. This includes developing cannabis-based therapies for specific medical conditions and working with healthcare professionals to promote their use. The medical cannabis market is expected to continue to grow as more research supports the therapeutic benefits of cannabis. Timeline: Ongoing, with a focus on clinical trials and regulatory approvals over the next 3-5 years.

Fırsatlar

  • Expansion into new legal cannabis markets.
  • Development of new cannabis-based products.
  • Strategic partnerships and acquisitions.
  • Growing demand for medical cannabis.

Tehditler

  • Regulatory uncertainty and changes in cannabis laws.
  • Intense competition from other cannabis producers.
  • Price volatility in the cannabis market.
  • Challenges of operating in the OTC market.

Rekabet Avantajları

  • Vertically integrated operations provide cost control and quality assurance.
  • Proprietary cultivation and processing techniques.
  • Established relationships with dispensaries and retailers.
  • Brand recognition in specific markets.

GNRSW Hakkında

Greenrose Holding Company Inc., established in 2014 and headquartered in Amityville, New York, operates in the cannabis industry through its subsidiaries. The company focuses on the production and sale of cannabis products, specifically engaging in the cultivation, processing, and packaging of medical cannabis and derivative products. This includes a range of cannabis-based medications and related items aimed at addressing various medical needs. The company's business model centers around vertically integrated operations, controlling the process from cultivation to final product distribution. This allows Greenrose to maintain quality control and potentially capture higher margins throughout the value chain. Greenrose's products are targeted towards patients and consumers in jurisdictions where medical cannabis is legal. The company navigates a complex regulatory environment, adhering to state and local laws governing cannabis production and sales. Greenrose aims to expand its market presence and product offerings, capitalizing on the increasing acceptance and legalization of cannabis for medical purposes. The company faces competition from other cannabis producers and pharmaceutical companies exploring cannabis-based therapies. Greenrose’s success depends on its ability to efficiently manage its operations, innovate in product development, and adapt to the changing regulatory landscape.

Ne Yaparlar

  • Cultivates medical cannabis.
  • Processes raw cannabis into usable forms.
  • Packages cannabis products for distribution.
  • Sells medical cannabis products to patients and consumers.
  • Develops derivative cannabis products.
  • Operates in jurisdictions where medical cannabis is legal.

İş Modeli

  • Vertically integrated operations from cultivation to distribution.
  • Focus on medical cannabis products.
  • Sales through dispensaries and other retail channels.
  • Revenue generated from the sale of cannabis products.

Sektör Bağlamı

Greenrose Holding Company Inc. operates within the rapidly evolving cannabis industry, which is experiencing significant growth due to increasing legalization and acceptance of cannabis for medical and recreational purposes. The market is characterized by intense competition, with numerous companies vying for market share. Greenrose competes with both established cannabis producers and pharmaceutical companies exploring cannabis-based therapies. The industry is subject to complex and changing regulations, which pose challenges and opportunities for companies like Greenrose. The global legal cannabis market is projected to reach billions of dollars in the coming years, presenting significant growth potential for companies that can navigate the regulatory landscape and establish a strong market position.

Kilit Müşteriler

  • Patients with medical conditions that qualify for medical cannabis use.
  • Consumers in jurisdictions where recreational cannabis is legal.
  • Dispensaries and retail stores that sell cannabis products.
  • Healthcare professionals who recommend medical cannabis to their patients.
AI Güveni: 67% Güncellendi: 18 Mar 2026

Finansallar

Grafik & Bilgi

Greenrose Acquisition Corp. (GNRSW) hisse senedi fiyatı: Price data unavailable

Son Haberler

GNRSW için son haber bulunmamaktadır.

Analist Konsensüsü

Fikir Birliği Derecelendirmesi

GNRSW için Benzinga, Yahoo Finance ve Finnhub'dan toplanan Al/Tut/Sat önerileri.

Fiyat Hedefleri

GNRSW için Wall Street fiyat hedefi analizi.

MoonshotScore

43/100

Bu puan ne anlama geliyor?

MoonshotScore, GNRSW'ın büyüme potansiyelini inovasyon, pazar yıkımı, finansal sağlık ve momentum dahil olmak üzere birden fazla faktörde 0-100 ölçeğinde derecelendirir.

Yönetim: Nicole Conboy

CEO

Nicole Conboy serves as the CEO of Greenrose Holding Company Inc. Information regarding her detailed career history, education, and previous roles is not available in the provided data. Therefore, a comprehensive background profile cannot be constructed. Further research would be required to ascertain her specific qualifications and experience in the cannabis industry or related fields.

Sicil: Due to the limited information available, it is not possible to assess Nicole Conboy's track record at Greenrose Holding Company Inc. or in previous roles. Key achievements, strategic decisions, and company milestones under her leadership cannot be determined based on the provided data. Further research would be necessary to evaluate her performance and contributions to the company.

GNRSW OTC Piyasa Bilgileri

The OTC Other tier represents the lowest tier of the OTC market, indicating that Greenrose Holding Company Inc. may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not be subject to the same level of regulatory scrutiny as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries a higher degree of risk due to the potential for limited information and liquidity.

  • OTC Katmanı: OTC Other
  • Açıklama Durumu: Unknown
Likidite: Liquidity for GNRSW is likely to be limited due to its OTC listing and unknown disclosure status. This can result in wider bid-ask spreads and difficulty in buying or selling shares without significantly impacting the price. Low trading volume can also increase the risk of price manipulation and make it challenging to exit a position quickly. Investors should be aware of these liquidity risks before investing.
OTC Risk Faktörleri:
  • Limited financial disclosure increases the risk of investing in GNRSW.
  • Low trading volume and liquidity can lead to price volatility.
  • OTC listing indicates a higher risk profile compared to major exchanges.
  • Regulatory uncertainty in the cannabis industry adds to the risk.
  • Potential for price manipulation due to limited oversight.
Durum Tespiti Kontrol Listesi:
  • Verify the company's financial statements and audit reports.
  • Research the company's management team and their experience.
  • Assess the company's competitive position in the cannabis market.
  • Evaluate the company's compliance with regulatory requirements.
  • Understand the risks associated with investing in OTC stocks.
  • Monitor trading volume and price movements closely.
  • Consult with a financial advisor before investing.
Meşruiyet Sinyalleri:
  • The company has been in operation since 2014.
  • It is involved in the production and sale of cannabis products.
  • The company has a reported profit margin of 70.6%.
  • The company employs 91 people.

Greenrose Acquisition Corp. Hissesi: Cevaplanan Temel Sorular

GNRSW için değerlendirilmesi gereken temel faktörler nelerdir?

Greenrose Acquisition Corp. (GNRSW) şu anda yapay zeka skoru 43/100, düşük puanı gösteriyor. Temel güçlü yan: Vertically integrated operations.. İzlenmesi gereken birincil risk: Potential: Regulatory uncertainty and changes in cannabis laws could negatively impact the company's operations.. Bu bir finansal tavsiye değildir.

GNRSW MoonshotScore'u nedir?

GNRSW şu anda MoonshotScore'da 43/100 (Derece D) alıyor, bu da düşük derecelendirme gösteriyor. Puan, 9 kantitatif KPI genelinde büyüme potansiyelini, finansal sağlığı, piyasa momentumunu ve risk faktörlerini değerlendirir. En son piyasa verileri kullanılarak günlük olarak yeniden hesaplanır. Bu puan yalnızca bilgilendirme amaçlıdır.

GNRSW verileri ne sıklıkla güncellenir?

GNRSW fiyatları ABD piyasa saatleri (hafta içi 9:30-16:00 ET) sırasında gerçek zamanlı olarak güncellenir. Temeller, üç aylık veya yıllık beyanlardan sonra yenilenir. Analist derecelendirmeleri ve yapay zeka öngörüleri günlük olarak güncellenir. Haberler, finans kaynaklarından sürekli olarak toplanır.

Analistler GNRSW hakkında ne diyor?

GNRSW için analist kapsamı, büyük araştırma şirketlerinden fikir birliği derecelendirmelerini (al, tut, sat), 12 aylık fiyat hedeflerini ve kazanç tahminlerini içerir. Temel veri noktaları: fikir birliği hedef fiyatı, kapsayan analist sayısı, son yükseltmeler veya düşürmeler ve kazanç beklentilerini aşma/aşamama geçmişi. Bu sayfadaki Analist Konsensüsü bölümüne bakın.

GNRSW'a yatırım yapmanın riskleri nelerdir?

GNRSW için risk kategorileri arasında piyasa riski, şirkete özgü risk (yönetim, rekabet), finansal risk (borç, nakit yakımı) ve makroekonomik risk (oranlar, enflasyon) yer alır. Yapay zeka analizi tarafından belirlenen önemli bir risk: Potential: Regulatory uncertainty and changes in cannabis laws could negatively impact the company's operations.. 1,0'ın üzerindeki beta, S&P 500'den daha yüksek volatiliteyi gösterir. Ayrıntılar için bu sayfadaki Risk Faktörleri bölümünü inceleyin. Tüm yatırımlar kayıp riski taşır.

GNRSW'ın P/E oranı nedir?

GNRSW için P/E (fiyat-kazanç) oranı, mevcut hisse senedi fiyatını hisse başına kazancıyla karşılaştırır. Daha yüksek bir P/E büyüme beklentilerini gösterebilirken, daha düşük bir P/E değer veya azalan kazançlar gösterebilir. Anlamlı bir bağlam için GNRSW'ın P/E'sini sektördeki emsalleriyle ve S&P 500 ortalamasıyla karşılaştırın. Mevcut değerleme metrikleri için Finansallar sekmesini kontrol edin.

GNRSW aşırı değerli mi, yoksa düşük değerli mi?

Greenrose Acquisition Corp. (GNRSW)'ın aşırı değerli mi yoksa düşük değerli mi olduğunu belirlemek, birden fazla metriği incelemeyi gerektirir. Kapsamlı bir görünüm için değerleme oranlarını (P/E, P/S, EV/EBITDA) sektördeki emsallerle karşılaştırın. Bu bir finansal tavsiye değildir.

GNRSW'ın temettü verimi nedir?

Greenrose Acquisition Corp. (GNRSW) şu anda düzenli bir temettü ödemiyor veya temettü verimi verileri mevcut değil. Büyüme odaklı şirketler genellikle temettü ödemek yerine karları yeniden yatırır. En son temettü bilgileri ve ödeme geçmişi için Finansallar sekmesini kontrol edin.

Sorumluluk reddi: Bu içerik yalnızca bilgilendirme amaçlıdır ve yatırım tavsiyesi teşkil etmez. Her zaman kendi araştırmanızı yapın ve bir finans uzmanına danışın.

Resmi Kaynaklar

Analiz güncellendi AI Puanı günlük olarak yenilenir
Veri Kaynakları ve Metodoloji
Piyasa verileri Financial Modeling Prep ve Yahoo Finance tarafından sağlanmaktadır. AI analizi Stock Expert AI tescilli algoritmaları ile yapılmaktadır. Teknik göstergeler endüstri standardı hesaplamalarla üretilmektedir. Son güncelleme: .

Veriler yalnızca bilgilendirme amaçlı sağlanmıştır.

Analiz Notları
  • Limited information available on the company's financials and operations.
  • OTC listing indicates higher risk and lower liquidity.
  • Analyst coverage is limited due to the company's size and OTC listing.
Veri Kaynakları

Popüler Hisseler